Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis

• Những tác giả chính: Xueyan Liang (Tác giả), Xiaoyu Chen (Tác giả), Huijuan Li (Tác giả), Xiaoxia Liu (Tác giả), Yan Li (Tác giả)
• Định dạng: Sách
• Được phát hành: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• Những chủ đề: article
• Truy cập trực tuyến: Connect to this object online.

BackgroundSugemalimab is a newly developed inhibitor of programmed death ligand 1 (PD-L1). As a first-line treatment for metastatic non-small-cell lung cancer (NSCLC), sugemalimab plus chemotherapy (Sugema-Chemo) has been proven effective. Still, its cost-effectiveness has not yet been determined. T...